These preclinical findings could prospectively help to analyse patients’ tumours pre-therapeutically in order to selectively find patients with COX-2-overexpressing tumours as inclusion criteria for successful tumour treatment with FAAH inhibitors. This evidence concerns the gene FAAH and neoplasm.